Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The 150/30 formulation. Experience in the United Kingdom.

J Guillebaud

    The Journal of Reproductive Medicine
    |January 1, 1983
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Intrauterine contraception - what now and what next?

    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2014
    Same author

    Intrauterine contraception: an update.

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2008
    Same author

    Effect of FTY720 on apoptosis of smooth muscle cells.

    Transplantation proceedings·2007
    Same author

    Contraception for the older woman: an update.

    Climacteric : the journal of the International Menopause Society·2006
    Same author

    Depot medroxyprogesterone and bone mineral density.

    The journal of family planning and reproductive health care·2005
    Same author

    Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women.

    Human reproduction (Oxford, England)·2005

    Low-dose oral contraceptives (OCs) with levonorgestrel and ethinyl estradiol offer high user satisfaction due to acceptable bleeding patterns and fewer side effects. Effectiveness is comparable to higher-dose options, though compliance is key for preventing unintended pregnancies.

    Area of Science:

    • Reproductive Medicine
    • Pharmacology
    • Women's Health

    Background:

    • Levonorgestrel 150mcg/ethinyl estradiol 30mcg oral contraceptives (OCs) dominate UK sales.
    • This formulation's success stems from low hormone doses and favorable bleeding profiles.

    Purpose of the Study:

    • To evaluate the efficacy and safety of a low-dose oral contraceptive formulation.
    • To assess user satisfaction regarding bleeding patterns and side effects.

    Main Methods:

    • Analysis of sales data for oral contraceptive agents in the UK.
    • Review of user data on bleeding patterns, cycle length, and side effects.
    • Comparison of contraceptive effectiveness with higher-dose formulations.

    Main Results:

    Keywords:
    Blood PressureClinical ResearchContraceptionContraceptive AgentsContraceptive Agents, FemaleContraceptive MethodsContraceptive Methods--side effectsContraceptive UsageDepressionDeveloped CountriesEthinyl EstradiolEuropeEvaluationFamily PlanningHeadacheLevonorgestrelMammary Gland EffectsMethod AcceptabilityNauseaNorthern EuropeOral Contraceptives, Low-doseOral Contraceptives--side effectsReproductive Control AgentsResearch MethodologySmokingUnited KingdomVomiting

    Related Experiment Videos

    • Breakthrough bleeding incidence was ~6%, amenorrhea <3%.
    • 90% of users experienced cycle lengths of 28 +/- 3 days.
    • Serious side effect risk is lower than with higher-dose OCs; headache reported in ~10% of cycles.

    Conclusions:

    • The 150/30mcg OC formulation provides an acceptable bleeding pattern and safety profile.
    • Contraceptive effectiveness is comparable to higher-dose OCs, but user compliance is crucial for efficacy.